On October 20, Sofinnova Partners, acting on behalf of a fund, declared to the AMF that it had fallen below the threshold of 10% of Abivax's voting rights, and held 8.37% of the capital and 9.93% of the voting rights, following a capital increase by Abivax.

Similarly, Truffle Capital, acting on behalf of funds, declared that on October 24 it had crossed below the thresholds of 15% of voting rights and 10% of capital in Abivax, and held 7.86% of capital and 13.00% of voting rights in the biotech company.

Copyright (c) 2023 CercleFinance.com. All rights reserved.